Loading…

Preformulation of FK506 Prodrugs for Improving Solubility

In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506‐G or FK506‐S) such as FK506‐M32‐LS‐G (FK506‐G) and FK506‐M32‐LS‐SL (FK506‐S) were synthesized. Two prodrugs (FK506‐G or FK506‐S), including FK506, were characterized by differential scanning calorimetr...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of the Korean Chemical Society 2016, 37(8), , pp.1313-1319
Main Authors: Na, Young-Guk, Jun, Hye-Suk, Kim, Daehee, Park, Byong-Chul, Lim, Si-Kyu, Lee, Ki-Ho, Hwang, Sung-Joo, Park, Jeong-Sook, Jung, Sang-Hun, Cho, Cheong-Weon
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3441-2fd2ddbbde3cba38060ee51e0ac9ed429accdfd875a70b62cd3adbc426c2b46c3
cites cdi_FETCH-LOGICAL-c3441-2fd2ddbbde3cba38060ee51e0ac9ed429accdfd875a70b62cd3adbc426c2b46c3
container_end_page 1319
container_issue 8
container_start_page 1313
container_title Bulletin of the Korean Chemical Society
container_volume 37
creator Na, Young-Guk
Jun, Hye-Suk
Kim, Daehee
Park, Byong-Chul
Lim, Si-Kyu
Lee, Ki-Ho
Hwang, Sung-Joo
Park, Jeong-Sook
Jung, Sang-Hun
Cho, Cheong-Weon
description In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506‐G or FK506‐S) such as FK506‐M32‐LS‐G (FK506‐G) and FK506‐M32‐LS‐SL (FK506‐S) were synthesized. Two prodrugs (FK506‐G or FK506‐S), including FK506, were characterized by differential scanning calorimetry (DSC), X‐ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506‐G or FK506‐S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506‐S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506‐G or FK506‐S) in human plasma was evaluated by measuring the decrease of FK506‐G or FK506‐S as well as the increase of FK506 by HPLC, and FK506‐G or FK506‐S was metabolized in 1 h in human plasma. Two prodrugs (FK506‐G or FK506‐S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506‐G, or 480.1 μg/mL for FK506‐S against a conjunctive cell line, Clone 1‐5c‐4 cells. Taken together, FK506‐S could be the most optimal prodrug for aqueous preparations based on preformulation data.
doi_str_mv 10.1002/bkcs.10861
format article
fullrecord <record><control><sourceid>istex_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_806968</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_LZ913CSB_2</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3441-2fd2ddbbde3cba38060ee51e0ac9ed429accdfd875a70b62cd3adbc426c2b46c3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AYhBdRsFYv_oIcRYjuR7LJHttga2nRYiuCl2W_Utak3bLbqv33po2KJ08z8D4z8A4AlwjeIAjxraxUaFxO0RHoIIxZnLKEHf_xp-AshLeGzTKcdgCbelM6v9zWYmPdKnJlNBinkEZT77TfLkLUXKPRcu3du10topmrt9LWdrM7ByelqIO5-NYueB7czYv7ePI4HBW9SaxIkqAYlxprLaU2RElBckihMSkyUChmdIKZUEqXOs9SkUFJsdJEaKkSTBWWCVWkC67a3pUveaUsd8IedOF45XnvaT7iTSujeYNet6jyLoTmMb72din8jiPI9_vw_T78sE8Doxb-sLXZ_UPy_riY_WTiNmPDxnz-ZoSvOM1IlvKXhyGfvDJEilmfY_IFFdp3sA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Preformulation of FK506 Prodrugs for Improving Solubility</title><source>Wiley</source><creator>Na, Young-Guk ; Jun, Hye-Suk ; Kim, Daehee ; Park, Byong-Chul ; Lim, Si-Kyu ; Lee, Ki-Ho ; Hwang, Sung-Joo ; Park, Jeong-Sook ; Jung, Sang-Hun ; Cho, Cheong-Weon</creator><creatorcontrib>Na, Young-Guk ; Jun, Hye-Suk ; Kim, Daehee ; Park, Byong-Chul ; Lim, Si-Kyu ; Lee, Ki-Ho ; Hwang, Sung-Joo ; Park, Jeong-Sook ; Jung, Sang-Hun ; Cho, Cheong-Weon</creatorcontrib><description>In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506‐G or FK506‐S) such as FK506‐M32‐LS‐G (FK506‐G) and FK506‐M32‐LS‐SL (FK506‐S) were synthesized. Two prodrugs (FK506‐G or FK506‐S), including FK506, were characterized by differential scanning calorimetry (DSC), X‐ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506‐G or FK506‐S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506‐S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506‐G or FK506‐S) in human plasma was evaluated by measuring the decrease of FK506‐G or FK506‐S as well as the increase of FK506 by HPLC, and FK506‐G or FK506‐S was metabolized in 1 h in human plasma. Two prodrugs (FK506‐G or FK506‐S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506‐G, or 480.1 μg/mL for FK506‐S against a conjunctive cell line, Clone 1‐5c‐4 cells. Taken together, FK506‐S could be the most optimal prodrug for aqueous preparations based on preformulation data.</description><identifier>ISSN: 1229-5949</identifier><identifier>ISSN: 0253-2964</identifier><identifier>EISSN: 1229-5949</identifier><identifier>DOI: 10.1002/bkcs.10861</identifier><language>eng</language><publisher>Weinheim: Wiley-VCH Verlag GmbH &amp; Co. KGaA</publisher><subject>Cytotoxicity ; FK506 ; Preformulation ; Prodrug ; Solubility ; 화학</subject><ispartof>Bulletin of the Korean Chemical Society, 2016, 37(8), , pp.1313-1319</ispartof><rights>2016 Korean Chemical Society, Seoul &amp; Wiley‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3441-2fd2ddbbde3cba38060ee51e0ac9ed429accdfd875a70b62cd3adbc426c2b46c3</citedby><cites>FETCH-LOGICAL-c3441-2fd2ddbbde3cba38060ee51e0ac9ed429accdfd875a70b62cd3adbc426c2b46c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002132093$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Na, Young-Guk</creatorcontrib><creatorcontrib>Jun, Hye-Suk</creatorcontrib><creatorcontrib>Kim, Daehee</creatorcontrib><creatorcontrib>Park, Byong-Chul</creatorcontrib><creatorcontrib>Lim, Si-Kyu</creatorcontrib><creatorcontrib>Lee, Ki-Ho</creatorcontrib><creatorcontrib>Hwang, Sung-Joo</creatorcontrib><creatorcontrib>Park, Jeong-Sook</creatorcontrib><creatorcontrib>Jung, Sang-Hun</creatorcontrib><creatorcontrib>Cho, Cheong-Weon</creatorcontrib><title>Preformulation of FK506 Prodrugs for Improving Solubility</title><title>Bulletin of the Korean Chemical Society</title><addtitle>Bull. Korean Chem. Soc</addtitle><description>In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506‐G or FK506‐S) such as FK506‐M32‐LS‐G (FK506‐G) and FK506‐M32‐LS‐SL (FK506‐S) were synthesized. Two prodrugs (FK506‐G or FK506‐S), including FK506, were characterized by differential scanning calorimetry (DSC), X‐ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506‐G or FK506‐S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506‐S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506‐G or FK506‐S) in human plasma was evaluated by measuring the decrease of FK506‐G or FK506‐S as well as the increase of FK506 by HPLC, and FK506‐G or FK506‐S was metabolized in 1 h in human plasma. Two prodrugs (FK506‐G or FK506‐S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506‐G, or 480.1 μg/mL for FK506‐S against a conjunctive cell line, Clone 1‐5c‐4 cells. Taken together, FK506‐S could be the most optimal prodrug for aqueous preparations based on preformulation data.</description><subject>Cytotoxicity</subject><subject>FK506</subject><subject>Preformulation</subject><subject>Prodrug</subject><subject>Solubility</subject><subject>화학</subject><issn>1229-5949</issn><issn>0253-2964</issn><issn>1229-5949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AYhBdRsFYv_oIcRYjuR7LJHttga2nRYiuCl2W_Utak3bLbqv33po2KJ08z8D4z8A4AlwjeIAjxraxUaFxO0RHoIIxZnLKEHf_xp-AshLeGzTKcdgCbelM6v9zWYmPdKnJlNBinkEZT77TfLkLUXKPRcu3du10topmrt9LWdrM7ByelqIO5-NYueB7czYv7ePI4HBW9SaxIkqAYlxprLaU2RElBckihMSkyUChmdIKZUEqXOs9SkUFJsdJEaKkSTBWWCVWkC67a3pUveaUsd8IedOF45XnvaT7iTSujeYNet6jyLoTmMb72din8jiPI9_vw_T78sE8Doxb-sLXZ_UPy_riY_WTiNmPDxnz-ZoSvOM1IlvKXhyGfvDJEilmfY_IFFdp3sA</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Na, Young-Guk</creator><creator>Jun, Hye-Suk</creator><creator>Kim, Daehee</creator><creator>Park, Byong-Chul</creator><creator>Lim, Si-Kyu</creator><creator>Lee, Ki-Ho</creator><creator>Hwang, Sung-Joo</creator><creator>Park, Jeong-Sook</creator><creator>Jung, Sang-Hun</creator><creator>Cho, Cheong-Weon</creator><general>Wiley-VCH Verlag GmbH &amp; Co. KGaA</general><general>Wiley‐VCH Verlag GmbH &amp; Co. KGaA</general><general>대한화학회</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ACYCR</scope></search><sort><creationdate>201608</creationdate><title>Preformulation of FK506 Prodrugs for Improving Solubility</title><author>Na, Young-Guk ; Jun, Hye-Suk ; Kim, Daehee ; Park, Byong-Chul ; Lim, Si-Kyu ; Lee, Ki-Ho ; Hwang, Sung-Joo ; Park, Jeong-Sook ; Jung, Sang-Hun ; Cho, Cheong-Weon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3441-2fd2ddbbde3cba38060ee51e0ac9ed429accdfd875a70b62cd3adbc426c2b46c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cytotoxicity</topic><topic>FK506</topic><topic>Preformulation</topic><topic>Prodrug</topic><topic>Solubility</topic><topic>화학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Na, Young-Guk</creatorcontrib><creatorcontrib>Jun, Hye-Suk</creatorcontrib><creatorcontrib>Kim, Daehee</creatorcontrib><creatorcontrib>Park, Byong-Chul</creatorcontrib><creatorcontrib>Lim, Si-Kyu</creatorcontrib><creatorcontrib>Lee, Ki-Ho</creatorcontrib><creatorcontrib>Hwang, Sung-Joo</creatorcontrib><creatorcontrib>Park, Jeong-Sook</creatorcontrib><creatorcontrib>Jung, Sang-Hun</creatorcontrib><creatorcontrib>Cho, Cheong-Weon</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>Korean Citation Index</collection><jtitle>Bulletin of the Korean Chemical Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Na, Young-Guk</au><au>Jun, Hye-Suk</au><au>Kim, Daehee</au><au>Park, Byong-Chul</au><au>Lim, Si-Kyu</au><au>Lee, Ki-Ho</au><au>Hwang, Sung-Joo</au><au>Park, Jeong-Sook</au><au>Jung, Sang-Hun</au><au>Cho, Cheong-Weon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preformulation of FK506 Prodrugs for Improving Solubility</atitle><jtitle>Bulletin of the Korean Chemical Society</jtitle><addtitle>Bull. Korean Chem. Soc</addtitle><date>2016-08</date><risdate>2016</risdate><volume>37</volume><issue>8</issue><spage>1313</spage><epage>1319</epage><pages>1313-1319</pages><issn>1229-5949</issn><issn>0253-2964</issn><eissn>1229-5949</eissn><abstract>In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506‐G or FK506‐S) such as FK506‐M32‐LS‐G (FK506‐G) and FK506‐M32‐LS‐SL (FK506‐S) were synthesized. Two prodrugs (FK506‐G or FK506‐S), including FK506, were characterized by differential scanning calorimetry (DSC), X‐ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506‐G or FK506‐S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506‐S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506‐G or FK506‐S) in human plasma was evaluated by measuring the decrease of FK506‐G or FK506‐S as well as the increase of FK506 by HPLC, and FK506‐G or FK506‐S was metabolized in 1 h in human plasma. Two prodrugs (FK506‐G or FK506‐S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506‐G, or 480.1 μg/mL for FK506‐S against a conjunctive cell line, Clone 1‐5c‐4 cells. Taken together, FK506‐S could be the most optimal prodrug for aqueous preparations based on preformulation data.</abstract><cop>Weinheim</cop><pub>Wiley-VCH Verlag GmbH &amp; Co. KGaA</pub><doi>10.1002/bkcs.10861</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1229-5949
ispartof Bulletin of the Korean Chemical Society, 2016, 37(8), , pp.1313-1319
issn 1229-5949
0253-2964
1229-5949
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_806968
source Wiley
subjects Cytotoxicity
FK506
Preformulation
Prodrug
Solubility
화학
title Preformulation of FK506 Prodrugs for Improving Solubility
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T20%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preformulation%20of%20FK506%20Prodrugs%20for%20Improving%20Solubility&rft.jtitle=Bulletin%20of%20the%20Korean%20Chemical%20Society&rft.au=Na,%20Young-Guk&rft.date=2016-08&rft.volume=37&rft.issue=8&rft.spage=1313&rft.epage=1319&rft.pages=1313-1319&rft.issn=1229-5949&rft.eissn=1229-5949&rft_id=info:doi/10.1002/bkcs.10861&rft_dat=%3Cistex_nrf_k%3Eark_67375_WNG_LZ913CSB_2%3C/istex_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3441-2fd2ddbbde3cba38060ee51e0ac9ed429accdfd875a70b62cd3adbc426c2b46c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true